Trial Profile
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms RESI
- 02 Jun 2016 Patients are receiving Rebif/Avonex now. Thus changes in purpose, primary end points and treatment.
- 02 Jun 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
- 02 Jun 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017.